PropThink
View PropThink's Articles BY TICKER:
ABBV,
ACAD,
ACHN,
ACRX,
AFFY,
ALXA,
ALXN,
AMED,
AMGN,
AMPE,
AMRN,
ANTH,
ARQL,
ASTM,
ASTX,
AUXL,
AVEO,
BCRX,
BIIB,
BLFS.OB,
BMRN,
CADX,
CBST,
CHTP,
CUR,
DARA,
DCTH,
DEPO,
DRRX,
ENDP,
EXAS,
GALE,
GERN,
GEVA,
HALO,
ICPT,
ILMN,
IMMU,
IMUC,
ISIS,
ITMN,
KERX,
LIFE,
MAKO,
MAPP,
MDVN,
MNOV,
MRGE,
NAVB,
NVIV.OB,
OHRP.OB,
ONTY,
ONVO.PK,
ONXX,
OPTR,
OREX,
OSUR,
PCYC,
PIP,
POZN,
QCOR,
REGN,
RMD,
RPTP,
SCLN,
SCMP,
SGMO,
SGYP,
SNTA,
SRPT,
SSH,
TELK,
TEVA,
THLD,
TKMR,
TKPHF.PK,
TSRX,
TTHI,
TTNP.OB,
UNIS,
VICL,
VPHM,
VRTX,
VRX,
XNPT,
ZGNX,
ZIOP,
ZLCS
-
Value Investors Take Note: Fire Sale On This Heart Failure Asset
- An FDA Meeting Becomes New Focus For Titan Pharma
- Trius Patent Intrigues Investors, And Perhaps Cubist Pharmaceuticals
- Markman Hearing A Likely Clearing Event For Cubist - Decision Any Day
- Does Cell Therapy Hold The Key To Treating Stroke?
- MAKO Surgical: Burden Of Proof Still On Management
-
Pounding The Table On Pozen: Why There's Upside In This Misunderstood Name
-
Regeneron: Solid Q1 Creates Platform For Further Upside
- Previewing MAKO Surgical's First Quarter: A Pivotal Earnings Release
- The ODAC Postmortem: Lessons Learned Part 2, Delcath Systems
- The ODAC Postmortem: Lessons Learned Part 1, AVEO
- Despite Poor Quarter, ViroPharma's Commercial And Pipeline Progress Continue
-
Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trial
- Durect: Pfizer Hints At Progress With Remoxy
- Watching Zalicus Like A Hawk
- Zogenix Poised For 40% Haircut As Zohydro Decision Approaches
- Undue Pressure On Trius Creates An Entrance Point
- FDA Rejection Of Probuphine Hits Titan Hard
- Weak Quarter At Auxilium Overshadows Execution On Long-Term Strategy
- Transition Therapeutics Still Undervalued: Good Trial Outcome Shifts Focus To Lilly Decision
- Raised Guidance And Resolved Manufacturing Issues Support Alexion Shares
- Synergy On Sale: Why This Opportunity Shouldn't Be Missed
- Illumina's Solid Quarter Highlights Macroeconomic Resilience, Market Opportunity
- Aveo's Inflection Point: Tivozanib Likely To Receive Positive Advisory Vote, FDA Approval
- The Beginning Of A Shift At Tekmira: From Focus On Delivery, To Therapy
- Keryx, Zerenex And IP Protection: A PropThink Conference Call
- Exact Sciences' Cancer Test Won't Be A Commercial Success
-
Intercept Pharmaceuticals: The Risks That No One Is Talking About
- FDA Bars Old OxyContin Generics: Read-Through To Continue Boosting Endo
-
Achillion: Moving Beyond Sofosbuvir's Shadow
- Sequencing Is Hot: Life Technologies Deal Has Implications For Illumina
- Here Are The Reasons To Own Keryx And Why Catalysts Are De-Risked